Herceptin 600mg (SC) Trastuzumab

Intended for healthcare professionals only

This material should not be used as a substitute for professional medical advice or to promote any medication. For more information, please consult your physician

Herceptin (Trastuzumab) SC is a subcutaneous formulation that contains hyaluronidase, which temporarily and reversibly degrades hyaluronan, a gel-like substance that forms a barrier between cells under the skin. This enables the subcutaneous formulation of Herceptin to be rapidly dispersed and absorbed over a greater area.

Herceptin SC, either alone or in combination with targeted therapies/chemotherapies is indicated for the treatment of patients with HER2-positive early breast cancer (EBC), and metastatic breast cancer (MBC).

If a patient becomes pregnant while receiving Herceptin, or within 7 months following the last dose of Herceptin, please immediately report pregnancy to the local Roche Adverse Event Line at +92 301 8287010 or email at [email protected]

Full prescribing information is available on request.
If you have a scientific query related to one of Roche's products, please contact us at [email protected]
In case of any adverse events or safety queries, please contact [email protected]

M-PK-00002297

Solutions

Pharma Products

See all Pharma Products